Physician Profile
Back to directory
Ajay Nooka MD, MPH
Hematologist
Bone Marrow and Stem Cell TransplantCAR T-Cell TherapyMultiple MyelomaPlasma Cell Disorders
Contact Information
Verified Physician Access
Phone numbers and email addresses are available to physicians verified by Winship Cancer Institute.
Treatment Locations
Emory University Hospital
Clinical Trials
Phase IISTUDY00003092
Maintenance Therapy With Belantamab, Pomalidomide and Dexamethasone (BPd) in High-Risk Myeloma Patients: A Phase 2 Study With a Safety Run-In
View
Phase IIISTUDY00006989
A Phase 3b, Multicenter, Open-label, Daratumumab Long-term Extension Study
View
Phase I2026P000170
A Modular, Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120, a Dual-targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19 in Participants With Multiple Myeloma (DURGA-2)
View
Phase I/IISTUDY00009087
A Phase Ib/II Study of AZD0120, Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against CD19 and B-cell Maturation Antigen (BCMA) in Participants With Relapsed/Refractory Multiple Myeloma (DURGA-1)
View
Phase IISTUDY00008486
MMRC Horizon One: A Phase II Randomized Adaptive Platform Trial Evaluating Novel Therapies in Relapsed or Refractory Multiple Myeloma (MMRC-099)
View
Phase I/IISTUDY00008466
Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol
View
Phase ISTUDY00008168
A Phase 1b, Dose Escalation/Dose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma
View